Coherus BioSciences’ (CHRS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the biotechnology company’s stock.

Separately, Robert W. Baird raised their price objective on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Stock Up 1.0 %

NASDAQ CHRS opened at $1.05 on Tuesday. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.64. The company has a market cap of $121.68 million, a price-to-earnings ratio of -13.13 and a beta of 0.92. The business’s fifty day moving average is $1.24 and its 200 day moving average is $1.19.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. State of Wyoming raised its position in Coherus BioSciences by 61.5% during the 4th quarter. State of Wyoming now owns 119,270 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 45,405 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Coherus BioSciences during the 4th quarter worth $345,000. Tang Capital Management LLC raised its position in Coherus BioSciences by 55.3% during the 4th quarter. Tang Capital Management LLC now owns 3,650,000 shares of the biotechnology company’s stock worth $5,037,000 after purchasing an additional 1,300,000 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Coherus BioSciences during the 4th quarter worth $7,291,000. Finally, Millennium Management LLC raised its position in Coherus BioSciences by 31.6% during the 4th quarter. Millennium Management LLC now owns 1,049,603 shares of the biotechnology company’s stock worth $1,448,000 after purchasing an additional 252,092 shares during the last quarter. 72.82% of the stock is owned by institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.